The active ingredient in NeuroSTAT, cyclosporin-A, has been used for immunosuppression such as in organ transplantation, NeuroVive said.
NeuroVive Pharma CEO Mikael Bronnegard said that the orphan drug designation gives access to important regulatory assistance which will greatly facilitate the development of neuroprotective therapy for acute treatment of patients with moderate and severe traumatic brain injury.
NeuroVive CSO Eskil Elmér said that NeuroSTAT cyclosporine has been shown to protect energy-producing mitochondria and counteract brain damage in TBI models.